Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX: V BTI) announces its board of directors elected by the shareholders at its Annual General Meeting held today:
Dr. Terry Pearson
Dr. Chris Fibiger
Michael Hutchison Q.C.
The Board also appointed the following officers of the Company:
Robin Hutchison, President and CEO
David Clark, Chief Financial Officer and Corporate Secretary
The Company also announces that is has granted as of close of business today 328,000 incentive stock options to officers and directors of the Company exercisable at $1.28 per share expiring on August 28, 2017. The options shall vest according to company’s stock option plan.
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest™, a blood test for the diagnosis of Alzheimer’s disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”
On Behalf of the Board of Directors
Robin Hutchison Chairman & CEO